Terns Pharmaceuticals TERN Stock
Terns Pharmaceuticals Price Chart
Terns Pharmaceuticals TERN Financial and Trading Overview
| Terns Pharmaceuticals stock price | 4.8 USD |
| Previous Close | 11.77 USD |
| Open | 11.69 USD |
| Bid | 0 USD x 1000 |
| Ask | 0 USD x 1200 |
| Day's Range | 11.16 - 11.69 USD |
| 52 Week Range | 1.79 - 14.04 USD |
| Volume | 522.43K USD |
| Avg. Volume | 492.38K USD |
| Market Cap | 650.69M USD |
| Beta (5Y Monthly) | -0.954341 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.27 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.29 USD |
TERN Valuation Measures
| Enterprise Value | 354.2M USD |
| Trailing P/E | N/A |
| Forward P/E | -8.258992 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 2.2616231 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -4.923 |
Trading Information
Terns Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | -0.954341 |
| 52-Week Change | 497.91% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 14.04 USD |
| 52 Week Low | 1.79 USD |
| 50-Day Moving Average | 11.99 USD |
| 200-Day Moving Average | 8.76 USD |
TERN Share Statistics
| Avg. Volume (3 month) | 492.38K USD |
| Avg. Daily Volume (10-Days) | 575.52K USD |
| Shares Outstanding | 56.68M |
| Float | 32.39M |
| Short Ratio | 5.93 |
| % Held by Insiders | 2.10% |
| % Held by Institutions | 93.60% |
| Shares Short | 3.12M |
| Short % of Float | 8.91% |
| Short % of Shares Outstanding | 5.51% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -19.75% |
| Return on Equity (ttm) | -31.20% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -71942000 USD |
| Net Income Avi to Common (ttm) | -68100000 USD |
| Diluted EPS (ttm) | -1.36 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 297.53M USD |
| Total Cash Per Share (mrq) | 5.25 USD |
| Total Debt (mrq) | 1.04M USD |
| Total Debt/Equity (mrq) | 0.36 USD |
| Current Ratio (mrq) | 24.747 |
| Book Value Per Share (mrq) | 5.076 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -50191000 USD |
| Levered Free Cash Flow (ttm) | -25743624 USD |
Profile of Terns Pharmaceuticals
| Country | United States |
| State | CA |
| City | Foster City |
| Address | 1065 East Hillsdale Boulevard |
| ZIP | 94404 |
| Phone | 650 525 5535 |
| Website | https://www.ternspharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 46 |
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of oncology, non-alcoholic steatohepatitis (NASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in clinical development for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Q&A For Terns Pharmaceuticals Stock
What is a current TERN stock price?
Terns Pharmaceuticals TERN stock price today per share is 4.8 USD.
How to purchase Terns Pharmaceuticals stock?
You can buy TERN shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Terns Pharmaceuticals?
The stock symbol or ticker of Terns Pharmaceuticals is TERN.
Which industry does the Terns Pharmaceuticals company belong to?
The Terns Pharmaceuticals industry is Biotechnology.
How many shares does Terns Pharmaceuticals have in circulation?
The max supply of Terns Pharmaceuticals shares is 69.23M.
What is Terns Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Terns Pharmaceuticals PE Ratio is now.
What was Terns Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Terns Pharmaceuticals EPS is -1.27 USD over the trailing 12 months.
Which sector does the Terns Pharmaceuticals company belong to?
The Terns Pharmaceuticals sector is Healthcare.
Terns Pharmaceuticals TERN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}